Skip to Content Facebook Feature Image

TELUS Health acquires Workplace Options, top provider of wellbeing services to Fortune 500 companies

Business

TELUS Health acquires Workplace Options, top provider of wellbeing services to Fortune 500 companies
Business

Business

TELUS Health acquires Workplace Options, top provider of wellbeing services to Fortune 500 companies

2025-05-14 21:54 Last Updated At:22:15

TELUS Health combines digital-first innovation with Workplace Options' Employee and Family Assistance Program to transform employee wellbeing solutions

GTCR to invest US$200 million as part of the acquisition, bringing strategic healthcare industry expertise to accelerate TELUS Health's global growth and innovation

VANCOUVER, BC and TORONTO, May 14, 2025 /PRNewswire/ -- TELUS Corporation ("TELUS") (TSX: T) (NYSE: TU) today announced a strategic partnership with GTCR, a leading private equity investor with extensive expertise across the healthcare landscape, supporting TELUS Health's recently announced acquisition of Workplace Options. Last week, TELUS Health announced the acquisition of Workplace Options for cash of approximately $500 million (US$350 million), net of assumed debt of approximately $100 million (US$70 million). Workplace Options, a leading global provider of integrated employee wellbeing solutions across 200 countries and territories, further solidifies TELUS Health as an unparalleled force in the global wellbeing solutions market. Today, TELUS Health is one of the largest companies providing digital-first health and wellbeing services and solutions globally to empower individuals to live their healthiest lives. TELUS Health is now positioned to support clients across all channels and global verticals covering more than 150 million lives and growing.

"Today marks a transformative milestone in our global health technology journey," said Darren Entwistle, President and CEO of TELUS. "By uniting TELUS Health and Workplace Options, we are creating an unprecedented breadth of experience and expertise that will drive global consistency in Employee and Family Assistance Programs (EFAP) and Wellbeing Solutions in a way that is unmatched in our industry. This acquisition furthers TELUS Health's practice of partnering with providers, digital health organizations, health plans and employers to create a more robust and localized offering executed at a global scale. This powerful combination, underpinned by TELUS' extensive AI expertise, ability to draw on common technologies, trends and advancements will unlock high-quality health outcomes for all constituents in a way previously unrealized. With more than 40-years of investment experience within the healthcare vertical, we look forward to GTCR's investment on this acquisition, who will be a value-added partner, supporting our efforts to accelerate growth."

"This is more than an acquisition, it's an extension of our vision to build one of the most comprehensive suites of health and wellbeing solutions globally," said Navin Arora, Executive Vice-president, TELUS and President, TELUS Business Solutions, TELUS Health, TELUS Agriculture & Consumer Goods, and TELUS Partner Solutions. "With our differentiated and complementary products and services and a strong base of local and multinational clients worldwide, we're excited about unlocking significant growth opportunities, new revenue streams and powerful economies of scale."

Benefits of the transaction:

  • Establishes a global network of more than 180,000 providers across more than 200 countries and territories, positioning TELUS Health as a leader in the global employer health and wellbeing space.
  • Delivers a standardized model for providing customers with robust EFAP and wellbeing services, backed by industry-leading customer experience support, global scale and reach.
  • Brings together TELUS' robust infrastructure and leading networks with Workplace Options' strong digital capabilities, as well as TELUS Digital's AI expertise, providing TELUS Health with a unique competitive advantage in the global market.

"By joining forces with TELUS Health, we are aligning with an organization that shares our deep commitment to innovation in EFAP solutions and our focus on delivering exceptional value to the reseller community," said Alan King, CEO, Workplace Options. "This acquisition by TELUS Health marks an exciting new chapter, uniting us in our mission to scaling what matters most: care, connection and trust in the workplace. TELUS Health's leading digital innovation will enable us to deliver unparalleled wellbeing services, ultimately transforming the health and productivity landscape."

GTCR brings over four decades of healthcare investment expertise to this strategic collaboration, having executed more than 65 platform healthcare investments and 250 healthcare transactions. GTCR will invest US$200 million as part of this acquisition, leveraging their deep industry knowledge and proven track record of successful corporate partnerships. GTCR is positioned as a strategic ally in support of TELUS Health's continued growth ambitions, while their participation in the Workplace Options transaction establishes the foundation for a long-term, value-generating partnership.

"We are thrilled to partner with TELUS Health to support its continued growth by leveraging both our deep expertise in the healthcare sector and ability to structure a bespoke transaction to meet the needs of our partner," said Dean Mihas, Co-CEO and Managing Director, GTCR. "Providing flexible capital solutions to outstanding management teams, coupled with a partnership approach to helping drive value creation through industry insights and experience, is core to GTCR's approach to delivering value to our portfolio companies, investors and other stakeholders."

About TELUS Health
TELUS Health is on a mission to become the most trusted wellbeing company in the world by enhancing the overall efficiency of healthcare and championing workplace wellbeing. By integrating advanced healthcare technology with comprehensive employee support services, TELUS Health provides a holistic approach to primary and preventive health and wellbeing enhancing more than 150 million lives across more than 200 countries and territories. Our innovative digital health platforms, including electronic medical records (EMRs) and virtual care solutions, empower healthcare professionals, employers and governments to deliver personalized care efficiently. Our employee wellbeing programs empower individuals by offering extensive support through Employee and Family Assistance Programs (EFAPs), mental health resources, financial counselling and workplace wellness initiatives. At TELUS Health, we are committed to revolutionizing healthcare to ensure people receive the support they need and employees thrive both personally and professionally. Together, let's make the future friendly. For more information please visit: www.telushealth.com.

For media inquiries, please contact:
Marielle Hossack
TELUS Health
marielle.hossack@telus.com

Investor Relations, please contact:
Ian McMillan
IR@telus.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

TELUS Health acquires Workplace Options, top provider of wellbeing services to Fortune 500 companies

TELUS Health acquires Workplace Options, top provider of wellbeing services to Fortune 500 companies

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Recommended Articles